In prostate cancer patients, decreased levels of PRUNE2 are indicative of poor prognosis, as this is associated with metastatic disease (National Center for Biotechnology Information, Gene Expression Omnibus, NCBI GEO, profile 34856174; n = 171) and a high Gleason score (The Cancer Genome Atlas, TCGA; n = 497). The gene discussed is PRUNE2; the disease is Familial prostate cancer.